Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Emergence Of New Myeloma Drugs, And Combinations, Raises Red Flag On Costs

Executive Summary

Combinations of two or more branded drugs likely mean better potency and sales across the board, but mounting costs are likely to raise red flag with payers.


Related Content

Multiple Myeloma Would Make Good Guinea Pig For Oncology Cost Control
J&J’s Oncology Strategy: Aim For Next-Gen Immuno-Oncology, More M&A
Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test


Related Companies